NVCR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 29, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 42 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 89%.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVCR as a result. In 70 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NVCR entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NVCR's RSI Indicator exited the oversold zone, 21 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 64 cases where NVCR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
Following a +10.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVCR advanced for three days, in 205 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
NVCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. NVCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.574) is normal, around the industry mean (4.142). P/E Ratio (-10.215) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (40.950) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
TWST saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 02, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 41 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The 10-day RSI Indicator for TWST moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 35 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 68 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
TWST moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TWST entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.967) is normal, around the industry mean (3.498). P/E Ratio (-54.166) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
NVCR | TWST | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 97 Overvalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 87 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 62 | 34 | |
P/E GROWTH RATING 1..100 | 26 | 85 | |
SEASONALITY SCORE 1..100 | 90 | 47 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TWST's Valuation (5) in the Biotechnology industry is significantly better than the same rating for NVCR (97) in the Medical Specialties industry. This means that TWST’s stock grew significantly faster than NVCR’s over the last 12 months.
TWST's Profit vs Risk Rating (87) in the Biotechnology industry is in the same range as NVCR (100) in the Medical Specialties industry. This means that TWST’s stock grew similarly to NVCR’s over the last 12 months.
TWST's SMR Rating (97) in the Biotechnology industry is in the same range as NVCR (98) in the Medical Specialties industry. This means that TWST’s stock grew similarly to NVCR’s over the last 12 months.
TWST's Price Growth Rating (34) in the Biotechnology industry is in the same range as NVCR (62) in the Medical Specialties industry. This means that TWST’s stock grew similarly to NVCR’s over the last 12 months.
NVCR's P/E Growth Rating (26) in the Medical Specialties industry is somewhat better than the same rating for TWST (85) in the Biotechnology industry. This means that NVCR’s stock grew somewhat faster than TWST’s over the last 12 months.
| NVCR | TWST | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 60% | 5 days ago 78% |
| Stochastic ODDS (%) | 4 days ago 73% | 4 days ago 85% |
| Momentum ODDS (%) | 4 days ago 86% | 4 days ago 89% |
| MACD ODDS (%) | 4 days ago 89% | 4 days ago 90% |
| TrendWeek ODDS (%) | 4 days ago 75% | 4 days ago 86% |
| TrendMonth ODDS (%) | 4 days ago 82% | 4 days ago 84% |
| Advances ODDS (%) | 6 days ago 75% | 6 days ago 81% |
| Declines ODDS (%) | 4 days ago 89% | 8 days ago 86% |
| BollingerBands ODDS (%) | 4 days ago 76% | 4 days ago 89% |
| Aroon ODDS (%) | 4 days ago 79% | 4 days ago 84% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVCR’s FA Score shows that 1 FA rating(s) are green while TWST’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVCR’s TA Score shows that 4 TA indicator(s) are bullish while TWST’s TA Score has 2 bullish TA indicator(s).
NVCR (@Medical/Nursing Services) experienced а +0.99% price change this week, while TWST (@Biotechnology) price change was -20.94% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +35.79%. For the same industry, the average monthly price growth was +17.54%, and the average quarterly price growth was +8.10%.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.
NVCR is expected to report earnings on Feb 25, 2027.
TWST is expected to report earnings on Nov 12, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Biotechnology (+2.97% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QQQI | 49.48 | 0.60 | +1.23% |
| NEOS Nasdaq 100 High Income ETF (QQQI) | |||
| JANP | 35.06 | 0.06 | +0.17% |
| PGIM S&P 500 Buffer 12 ETF - January (JANP) | |||
| TBLD | 20.11 | N/A | N/A |
| Thornburg Income Builder Opportunities Trust | |||
| WCBR | 41.76 | -0.22 | -0.51% |
| WisdomTree Cybersecurity Fund (WCBR) | |||
| COSW | 42.40 | -0.51 | -1.18% |
| Roundhill COST WeeklyPay ETF (COSW) | |||